The oncogenic MicroRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation

Su Jung Song, Keisuke Ito, Ugo Ala, Lev Kats, Kaitlyn Webster, Su Ming Sun, Mojca Jongen-Lavrencic, Katia Manova-Todorova, Julie Teruya-Feldstein, David E. Avigan, Ruud Delwel, Pier Paolo Pandolfi

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

MicroRNAs are frequently deregulated in cancer. Here we show that miR-22 is upregulated in myelodysplastic syndrome (MDS) and leukemia and its aberrant expression correlates with poor survival. To explore its role in hematopoietic stem cell function and malignancy, we generated transgenic mice conditionally expressing miR-22 in the hematopoietic compartment. These mice displayed reduced levels of global 5-hydroxymethylcytosine (5-hmC) and increased hematopoietic stem cell self-renewalaccompanied by defective differentiation. Conversely, miR- 22 inhibition blocked proliferation in both mouse and human leukemic cells. Over time, miR-22 transgenic mice developedMDSand hematological malignancies. We also identify TET2 as a key target of miR-22 in this context. Ectopic expression of TET2 suppressed the miR-22-induced phenotypes. Downregulation of TET2 protein also correlated with poor clinical outcomes and miR-22 overexpression in MDS patients. Our results therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-22/TET2 regulatory network are common in hematopoietic malignancies. 2013

Original languageEnglish (US)
Pages (from-to)87-101
Number of pages15
JournalCell Stem Cell
Volume13
Issue number1
DOIs
StatePublished - Jul 3 2013

Fingerprint

Myelodysplastic Syndromes
Hematologic Neoplasms
Hematopoietic Stem Cells
MicroRNAs
Transgenic Mice
Proto-Oncogenes
Neoplasms
Leukemia
Down-Regulation
Phenotype
Survival
Proteins
Cell Self Renewal
5-hydroxymethylcytosine
Ectopic Gene Expression

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics
  • Medicine(all)

Cite this

The oncogenic MicroRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. / Song, Su Jung; Ito, Keisuke; Ala, Ugo; Kats, Lev; Webster, Kaitlyn; Sun, Su Ming; Jongen-Lavrencic, Mojca; Manova-Todorova, Katia; Teruya-Feldstein, Julie; Avigan, David E.; Delwel, Ruud; Pandolfi, Pier Paolo.

In: Cell Stem Cell, Vol. 13, No. 1, 03.07.2013, p. 87-101.

Research output: Contribution to journalArticle

Song, SJ, Ito, K, Ala, U, Kats, L, Webster, K, Sun, SM, Jongen-Lavrencic, M, Manova-Todorova, K, Teruya-Feldstein, J, Avigan, DE, Delwel, R & Pandolfi, PP 2013, 'The oncogenic MicroRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation', Cell Stem Cell, vol. 13, no. 1, pp. 87-101. https://doi.org/10.1016/j.stem.2013.06.003
Song, Su Jung ; Ito, Keisuke ; Ala, Ugo ; Kats, Lev ; Webster, Kaitlyn ; Sun, Su Ming ; Jongen-Lavrencic, Mojca ; Manova-Todorova, Katia ; Teruya-Feldstein, Julie ; Avigan, David E. ; Delwel, Ruud ; Pandolfi, Pier Paolo. / The oncogenic MicroRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. In: Cell Stem Cell. 2013 ; Vol. 13, No. 1. pp. 87-101.
@article{7b6778d95c1f4a2f8928c3fd25ad19ac,
title = "The oncogenic MicroRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation",
abstract = "MicroRNAs are frequently deregulated in cancer. Here we show that miR-22 is upregulated in myelodysplastic syndrome (MDS) and leukemia and its aberrant expression correlates with poor survival. To explore its role in hematopoietic stem cell function and malignancy, we generated transgenic mice conditionally expressing miR-22 in the hematopoietic compartment. These mice displayed reduced levels of global 5-hydroxymethylcytosine (5-hmC) and increased hematopoietic stem cell self-renewalaccompanied by defective differentiation. Conversely, miR- 22 inhibition blocked proliferation in both mouse and human leukemic cells. Over time, miR-22 transgenic mice developedMDSand hematological malignancies. We also identify TET2 as a key target of miR-22 in this context. Ectopic expression of TET2 suppressed the miR-22-induced phenotypes. Downregulation of TET2 protein also correlated with poor clinical outcomes and miR-22 overexpression in MDS patients. Our results therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-22/TET2 regulatory network are common in hematopoietic malignancies. 2013",
author = "Song, {Su Jung} and Keisuke Ito and Ugo Ala and Lev Kats and Kaitlyn Webster and Sun, {Su Ming} and Mojca Jongen-Lavrencic and Katia Manova-Todorova and Julie Teruya-Feldstein and Avigan, {David E.} and Ruud Delwel and Pandolfi, {Pier Paolo}",
year = "2013",
month = "7",
day = "3",
doi = "10.1016/j.stem.2013.06.003",
language = "English (US)",
volume = "13",
pages = "87--101",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - The oncogenic MicroRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation

AU - Song, Su Jung

AU - Ito, Keisuke

AU - Ala, Ugo

AU - Kats, Lev

AU - Webster, Kaitlyn

AU - Sun, Su Ming

AU - Jongen-Lavrencic, Mojca

AU - Manova-Todorova, Katia

AU - Teruya-Feldstein, Julie

AU - Avigan, David E.

AU - Delwel, Ruud

AU - Pandolfi, Pier Paolo

PY - 2013/7/3

Y1 - 2013/7/3

N2 - MicroRNAs are frequently deregulated in cancer. Here we show that miR-22 is upregulated in myelodysplastic syndrome (MDS) and leukemia and its aberrant expression correlates with poor survival. To explore its role in hematopoietic stem cell function and malignancy, we generated transgenic mice conditionally expressing miR-22 in the hematopoietic compartment. These mice displayed reduced levels of global 5-hydroxymethylcytosine (5-hmC) and increased hematopoietic stem cell self-renewalaccompanied by defective differentiation. Conversely, miR- 22 inhibition blocked proliferation in both mouse and human leukemic cells. Over time, miR-22 transgenic mice developedMDSand hematological malignancies. We also identify TET2 as a key target of miR-22 in this context. Ectopic expression of TET2 suppressed the miR-22-induced phenotypes. Downregulation of TET2 protein also correlated with poor clinical outcomes and miR-22 overexpression in MDS patients. Our results therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-22/TET2 regulatory network are common in hematopoietic malignancies. 2013

AB - MicroRNAs are frequently deregulated in cancer. Here we show that miR-22 is upregulated in myelodysplastic syndrome (MDS) and leukemia and its aberrant expression correlates with poor survival. To explore its role in hematopoietic stem cell function and malignancy, we generated transgenic mice conditionally expressing miR-22 in the hematopoietic compartment. These mice displayed reduced levels of global 5-hydroxymethylcytosine (5-hmC) and increased hematopoietic stem cell self-renewalaccompanied by defective differentiation. Conversely, miR- 22 inhibition blocked proliferation in both mouse and human leukemic cells. Over time, miR-22 transgenic mice developedMDSand hematological malignancies. We also identify TET2 as a key target of miR-22 in this context. Ectopic expression of TET2 suppressed the miR-22-induced phenotypes. Downregulation of TET2 protein also correlated with poor clinical outcomes and miR-22 overexpression in MDS patients. Our results therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-22/TET2 regulatory network are common in hematopoietic malignancies. 2013

UR - http://www.scopus.com/inward/record.url?scp=84880571480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880571480&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2013.06.003

DO - 10.1016/j.stem.2013.06.003

M3 - Article

VL - 13

SP - 87

EP - 101

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 1

ER -